EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Anti–Methicillin-Resistant Staphylococcus aureus (MRSA) Cephalosporins Plus Daptomycin as Initial Therapy for MRSA Bacteremia: Does a “Hit Hard and Fast” Strategy Improve Outcomes?

Davide Fiore Bavaro, Alessandra Belati iD, Davide Sacchet iD, Alessandro Cilli, Lucia Diella, Daria Pocaterra, Maddalena Casana, Diletta Barbanotti, Paola Morelli, Luisa Frallonardo iD, Francesco Di Gennaro iD, Luigi Ronga und 13 weitere

Clinical Infectious Diseases · 2026

DOI: 10.1093/cid/ciag228 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Clinical Infectious Diseases, 2026. Verfasst von Davide Fiore Bavaro und 24 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy. Hauptthemen laut MEDLINE: Bacteremia, Methicillin-Resistant Staphylococcus aureus, Anti-Bacterial Agents, Daptomycin. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The study aim was to evaluate the effectiveness of anti–methicillin-resistant Staphylococcus aureus (MRSA) cephalosporins in combination with daptomycin (anti-MRSA Ceph + DAP) compared to other antimicrobial regimens (OARs) as initial treatment of MRSA bloodstream infection (BSI).

Methods

This retrospective observational study enrolled patients with MRSA-BSI from 1 January 2020 to 31 December 2024 at 4 large Italian hospitals. The primary endpoint was 90-day all-cause mortality. Cox regression was used for primary endpoint analysis; results were confirmed with inverse probability of treatment weighting (IPTW). Treatment efficacy was also assessed using the desirability of outcome ranking (DOOR) approach, assigning 1 additional point beyond recovery for 1 of the following negative outcomes: (i) persistent MRSA infection, (ii) persistent bacteremia (≥5 days), (iii) drug resistance, (iv) any adverse event, and (v) 90-day relapse. A score of 7 was assigned for death at any time point.

Results

Overall, 465 patients were enrolled: Median age was 76 (IQR, 61–83) years, 59% male, with a Charlson Comorbidity Index score of 7 (IQR, 4–8). Of them, 50 (11%) and 116 (25%) patients had endocarditis and metastatic infection, respectively. Importantly, 90-day mortality occurred in 181 (39%) patients, while 260 (56%) experienced at least 1 negative outcome included in DOOR analysis. Overall, patients in the anti-MRSA Ceph + DAP arm had a 59.9% (95% CI, 52.4%–67.4%) probability of having a better outcome than those in the OAR arm. Particularly, anti-MRSA Ceph + DAP was associated with reduced mortality (aHR, 0.54 [95% CI, .34–.85]), confirmed after adjustment with IPTW analysis.

Conclusions

Anti-MRSA Ceph + DAP could represent a valid initial therapy for MRSA-BSI, especially in patients with high risk of worse outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BacteremiaMethicillin-Resistant Staphylococcus aureusAnti-Bacterial AgentsDaptomycinStaphylococcal InfectionsCephalosporinsHumansMaleRetrospective StudiesFemaleMiddle AgedAgedAged, 80 and overTreatment OutcomeDrug Therapy, Combination

Stichwörter der Autor:innen

MRSA-BSIcombination therapymortalitytreatment failure

Substanzen

Anti-Bacterial AgentsDaptomycinCephalosporins

Autor:innen und Institutionen

  • Infectious Diseases Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy.
  • Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy.
  • Clinic of Infectious Diseases, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari "Aldo Moro," Bari, Italy.
  • Section of Microbiology and Virology, Polyclinic of Bari, University of Bari "Aldo Moro", Bari, Italy.
  • National PhD Programme in One Health Approaches to Infectious Diseases and Life Science Research, Department of Public Health, Experimental and Forensic Medicine, University of Pavia, Pavia, Italy.
  • Microbiology, IRCCS Humanitas Research Hospital, Rozzano, Italy.

ORCID-Profile: Alessandra Belati, Davide Sacchet, Luisa Frallonardo, Francesco Di Gennaro, Riccardo Bollini, Pierluigi Viale

Zitieren

APA

Bavaro, D. F., Belati, A., Sacchet, D., Cilli, A., Diella, L., Pocaterra, D., Casana, M., Barbanotti, D., Morelli, P., Frallonardo, L., Di Gennaro, F., Ronga, L., Bollini, R., Scuderi, C., Casari, E., Cento, V., Bussini, L., Patrucco, C., Pascale, R., …, & Bartoletti, M. (2026). Anti–Methicillin-Resistant Staphylococcus aureus (MRSA) Cephalosporins Plus Daptomycin as Initial Therapy for MRSA Bacteremia: Does a “Hit Hard and Fast” Strategy Improve Outcomes?. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciag228

Vancouver

Bavaro DF, Belati A, Sacchet D, Cilli A, Diella L, Pocaterra D, et al. Anti–Methicillin-Resistant Staphylococcus aureus (MRSA) Cephalosporins Plus Daptomycin as Initial Therapy for MRSA Bacteremia: Does a “Hit Hard and Fast” Strategy Improve Outcomes?. Clinical Infectious Diseases. 2026. doi:10.1093/cid/ciag228

BibTeX
@article{Bavaro2026,
  author = {Bavaro, Davide Fiore and Belati, Alessandra and Sacchet, Davide and Cilli, Alessandro and Diella, Lucia and Pocaterra, Daria and Casana, Maddalena and Barbanotti, Diletta and Morelli, Paola and Frallonardo, Luisa and Di Gennaro, Francesco and Ronga, Luigi and Bollini, Riccardo and Scuderi, Cristina and Casari, Erminia and Cento, Valeria and Bussini, Linda and Patrucco, Carolina and Pascale, Renato and Saracino, Annalisa and Berna, Giovanni and Carbonara, Sergio and Giannella, Maddalena and Viale, Pierluigi and Bartoletti, Michele},
  title = {Anti–Methicillin-Resistant Staphylococcus aureus (MRSA) Cephalosporins Plus Daptomycin as Initial Therapy for MRSA Bacteremia: Does a “Hit Hard and Fast” Strategy Improve Outcomes?},
  journal = {Clinical Infectious Diseases},
  year = {2026},
  doi = {10.1093/cid/ciag228}
}
Kostenlos starten →